- Conditions
- Non - Small Cell Lung Cancer NSCLC
- Interventions
- MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 33
- States / cities
- Chandler, Arizona • Anaheim, California • Duarte, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 101
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Filgotinib, Placebo, Standard of Care
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 21 Years to 65 Years · Male only
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 10
- States / cities
- San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin, Carboplatin, Stereotactic Body Radiotherapy
- Drug · Device
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Sleep Health, Stress, Anxiety, Physical Activity, Nutrition, Cognition
- Interventions
- Sleep enhancement intervention, Standard of Care (Investigator Choice)
- Behavioral
- Lead sponsor
- California Polytechnic State University-San Luis Obispo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Luis Obispo, California
- Conditions
- Breast Cancer, Colorectal Cancer, Cervical Cancer
- Interventions
- TopCare: Use of provider knowledge vs. automated system
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 103,870 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 9
- States / cities
- La Jolla, California • New Haven, Connecticut • Boca Raton, Florida + 6 more
- Conditions
- Influenza A
- Interventions
- Pimodivir 600 mg, Placebo, SOC Treatment
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 13 Years to 85 Years
- Enrollment
- 553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 140
- States / cities
- Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Manhasset, New York • Dallas, Texas
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 695 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 23
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 19 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-02341066, Pemetrexed, Docetaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 119
- States / cities
- Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 58 more
- Conditions
- Essential Tremor
- Interventions
- Alcohol, Alprazolam, Cold Therapy, Peripheral Nerve Stimulation
- Drug · Device · Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Atrial Fibrillation
- Interventions
- Edoxaban-based Regimen, VKA-based Regimen
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 60 more
- Conditions
- Amputation, Surgical
- Interventions
- K-Socket-Harness
- Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
- Interventions
- SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Rochester, Minnesota + 3 more
- Conditions
- Pain
- Interventions
- NESAP, 24% oral Sucrose, Sham NESAP, Oral water
- Device · Behavioral
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 1 Day to 3 Days
- Enrollment
- 162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas • Stanford, California
- Conditions
- Obesity, Morbid, Ventilator-Induced Lung Injury, Respiratory Failure
- Interventions
- Esophageal balloon, Intervention Spontaneous Breathing Trial (SBT) and Extubation, Control Spontaneous Breathing Trial and Extubation, Intervention Weaning after Tracheostomy, Control Weaning after Tracheostomy
- Device · Procedure
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Greenville, North Carolina
- Conditions
- Prostate Cancer
- Interventions
- eMRI/MRSI
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypertension, Heart Failure
- Interventions
- Clevidipine, Standard of Care IV antihypertensive
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 9
- States / cities
- Montgomery, Alabama • Inglewood, California • Baton Rouge, Louisiana + 6 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 30
- States / cities
- Springdale, Arkansas • Fullerton, California • Los Angeles, California + 24 more
- Conditions
- Hypertension, Physical Activity, Diet, Medication Adherence
- Interventions
- Therapeutic Lifestyle Changes (MINT-TLC), Usual Care
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Brooklyn, New York • New York, New York
- Conditions
- Advanced Cancer
- Interventions
- RBS2418, Pembrolizumab, Other approved anti-cancer therapy
- Drug
- Lead sponsor
- Riboscience, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 11 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
- Drug · Procedure
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 38
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 28 more
- Conditions
- Stroke Patients, CPAP, OSA - Obstructive Sleep Apnea
- Interventions
- CPAP device, CPAP technical support, Phone follow-up for adherence feedback and self-management skills, myAir, Tailored messages, Written Materials, Motivational Enhancement Therapy (MET)
- Device · Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Downey, California • Seattle, Washington
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
- Interventions
- CF-301, Placebo
- Biological · Drug
- Lead sponsor
- ContraFect
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more